ZA977687B - Substituted 6,5-hetero-bicyclic derivatives - Google Patents

Substituted 6,5-hetero-bicyclic derivatives

Info

Publication number: ZA977687B
Authority: ZA; South Africa
Prior art keywords: hetero; substituted; bicyclic derivatives; bicyclic; derivatives
Prior art date: 1996-08-28

Application number

ZA977687A

Other languages

English (en)

Inventor

Yuhpyng Liang Chen

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-28

Filing date

1997-08-27

Publication date

1999-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21823717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA977687(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-08-27 Application filed by Pfizer filed Critical Pfizer

1999-03-01 Publication of ZA977687B publication Critical patent/ZA977687B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Addiction (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)

ZA977687A 1996-08-28 1997-08-27 Substituted 6,5-hetero-bicyclic derivatives ZA977687B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2503996P	1996-08-28	1996-08-28

Publications (1)

Publication Number	Publication Date
ZA977687B true ZA977687B (en)	1999-03-01

Family

ID=21823717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA977687A ZA977687B (en)	1996-08-28	1997-08-27	Substituted 6,5-hetero-bicyclic derivatives

Country Status (36)

Country	Link
EP (1)	EP0923582B1 (no)
JP (2)	JP3621706B2 (no)
KR (1)	KR20000035934A (no)
CN (1)	CN1227554A (no)
AP (1)	AP762A (no)
AR (1)	AR015103A1 (no)
AT (1)	ATE340176T1 (no)
AU (1)	AU735401B2 (no)
BG (1)	BG103189A (no)
BR (1)	BR9711970A (no)
CA (1)	CA2263566C (no)
CO (1)	CO4600634A1 (no)
CZ (1)	CZ68199A3 (no)
DE (1)	DE69736711T2 (no)
DZ (1)	DZ2300A1 (no)
EA (1)	EA002769B1 (no)
ES (1)	ES2273369T3 (no)
GT (1)	GT199700095A (no)
HR (1)	HRP970454B1 (no)
HU (1)	HUP9903965A3 (no)
ID (1)	ID18249A (no)
IL (1)	IL127566A0 (no)
IS (1)	IS4963A (no)
MA (1)	MA26438A1 (no)
NO (1)	NO313636B1 (no)
NZ (1)	NZ333302A (no)
OA (1)	OA10977A (no)
PA (1)	PA8436201A1 (no)
PE (1)	PE108898A1 (no)
PL (1)	PL332040A1 (no)
SK (1)	SK23399A3 (no)
TN (1)	TNSN97145A1 (no)
TR (1)	TR199900389T2 (no)
TW (1)	TW575573B (no)
WO (1)	WO1998008847A1 (no)
ZA (1)	ZA977687B (no)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2194756A1 (en)	1995-05-12	1996-11-14	Jun Yuan	Novel deazapurine derivatives; a new class of crf1 specific ligands
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
US6124289A (en) *	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
US7094782B1 (en)	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
WO1998035967A2 (en)	1997-02-18	1998-08-20	Neurocrine Biosciences, Inc.	Biazacyclic crf antagonists
NZ335823A (en)	1997-04-22	2001-06-29	Neurocrine Biosciences Inc	Thiophenopyridines, preparation as CRF receptor antagonists
CA2294117A1 (en) *	1997-07-03	1999-01-14	Dupont Pharmaceuticals Company	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
ATE301657T1 (de) *	1998-01-28	2005-08-15	Bristol Myers Squibb Pharma Co	Azolo-pyrimidine
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
JP2002510686A (ja)	1998-04-02	2002-04-09	ニューロゲンコーポレイション	アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
US6472402B1 (en)	1998-04-02	2002-10-29	Neurogen Corporation	Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
JP2002510695A (ja) *	1998-04-03	2002-04-09	デュポンファーマシューティカルズカンパニー	副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
AU4556999A (en)	1998-06-09	1999-12-30	Neurogen Corporation	Pyrido[2,3-b]indolizine derivatives and aza analogues thereof; crf1 specific ligands
US6509338B1 (en)	1998-06-22	2003-01-21	Bristol-Myers Squibb Company	Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
AU5777299A (en)	1998-08-21	2000-03-14	Du Pont Pharmaceuticals Company	Isoxazolo(4,5-d)pyrimidines as CRF antagonists
ES2196898T3 (es) *	1998-11-12	2003-12-16	Neurocrine Biosciences Inc	Antagonistas de receptores de crf y metodos relacionados.
US6531475B1 (en) *	1998-11-12	2003-03-11	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
IL142893A0 (en)	1998-11-12	2002-04-21	Neurocrine Biosciences Inc	Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
WO2000044754A1 (fr) *	1999-01-29	2000-08-03	Sumitomo Chemical Company, Limited	Agents inhibiteurs d'accumulation de graisse
EP1040831A3 (en) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059907A2 (en)	1999-04-06	2000-10-12	Du Pont Pharmaceuticals Company	Pyrazolotriazines as crf antagonists
WO2000059908A2 (en) *	1999-04-06	2000-10-12	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
US6982265B1 (en)	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
EP1669071B1 (en) *	1999-05-21	2009-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6432989B1 (en) *	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
CZ20021086A3 (cs)	1999-09-30	2002-10-16	Neurogen Corporation	Alkylendiaminem substituované heterocykly
IL148905A0 (en)	1999-09-30	2002-09-12	Neurogen Corp Pfizer Inc	Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
SE9903544D0 (sv)	1999-10-01	1999-10-01	Astra Pharma Prod	Novel compounds
CO5271670A1 (es)	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) *	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB2359078A (en)	2000-02-11	2001-08-15	Astrazeneca Uk Ltd	Pharmaceutically active pyrimidine derivatives
GB2359081A (en) *	2000-02-11	2001-08-15	Astrazeneca Uk Ltd	Pharmaceutically active thiazolopyrimidines
EP1257555B1 (en) *	2000-02-11	2003-12-03	AstraZeneca AB	Pyrimidine compounds and their use as modulators of chemokine receptor activity
EP1293213A1 (en) *	2000-02-14	2003-03-19	Japan Tobacco Inc.	Preventives/remedies for postoperative stress
GB2359551A (en)	2000-02-23	2001-08-29	Astrazeneca Uk Ltd	Pharmaceutically active pyrimidine derivatives
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
US6440960B1 (en)	2000-05-18	2002-08-27	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
MXPA02010763A (es)	2000-06-14	2003-03-10	Warner Lambert Co	Heterociclicos biciclos-6,5 fusionados.
US6630476B2 (en) *	2000-07-07	2003-10-07	Bristol-Myers Squibb Pharma Company	Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
SE0003828D0 (sv)	2000-10-20	2000-10-20	Astrazeneca Ab	Novel compounds
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
DK1354884T3 (da)	2000-12-28	2008-03-03	Ono Pharmaceutical Co	Cyklopenta[d]pyrazolo[1,5-a]pyrimidinforbindelse som CRF-receptorantagonist
GB0100624D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
TWI312347B (en)	2001-02-08	2009-07-21	Eisai R&D Man Co Ltd	Bicyclic nitrogen-containing condensed ring compounds
BR0208357A (pt) *	2001-03-13	2004-06-29	Bristol Myers Squibb Pharma Co	Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
SE0101322D0 (sv)	2001-04-12	2001-04-12	Astrazeneca Ab	Novel compounds
MXPA03009738A (es)	2001-04-27	2004-01-29	Eisai Co Ltd	Pirazol [1,5-a] piridinas y medicinas que las contienen.
BR0209947A (pt) *	2001-05-21	2004-04-27	Neurocrine Inc	Derivados tri- e tetraaza-acenaftilen como antagonista do receptor de crf
GB0117396D0 (en) *	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
EP2335700A1 (en)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
ES2245772T3 (es)	2002-03-07	2006-01-16	Smithkline Beecham Corporation	Derivados de pirazolopirimidina y pirazolotriazina y composiciones farmaceuticas que los contienen.
EP1348707B1 (en) *	2002-03-28	2010-08-25	Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO)	Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
US7119200B2 (en) *	2002-09-04	2006-10-10	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0221828D0 (en)	2002-09-20	2002-10-30	Astrazeneca Ab	Novel compound
AR041470A1 (es) *	2002-10-17	2005-05-18	Upjohn Co	Compuestos de pirrolo (1,2 - b) piridazina y sus usos
WO2004037822A1 (ja)	2002-10-22	2004-05-06	Eisai Co., Ltd.	７−フェニルピラゾロピリジン化合物
US7176216B2 (en)	2002-10-22	2007-02-13	Eisai Co., Ltd.	7-phenylpyrazolopyridine compounds
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
GEP20084540B (en)	2003-01-14	2008-11-25	Arena Pharm Inc	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7041671B2 (en)	2003-04-02	2006-05-09	Pfizer Inc	Pyrrolo[1,2-b]pyridazine compounds and their uses
US7056920B2 (en) *	2003-04-04	2006-06-06	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
US7034023B2 (en) *	2003-04-04	2006-04-25	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
JP2006523675A (ja) *	2003-04-15	2006-10-19	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	ピロロ［１，２−ｂ］ピリダジン化合物及びそれらの使用
MXPA05011643A (es)	2003-04-29	2005-12-15	Pfizer Ltd	5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
BRPI0410097A (pt) *	2003-05-07	2006-05-16	Pharmacia & Upjohn Co Llc	compostos de pirrol[1,2-b]piridazina
WO2004110454A1 (ja) *	2003-06-13	2004-12-23	Ishihara Sangyo Kaisha, Ltd.	アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
TWI335328B (en)	2003-07-14	2011-01-01	Arena Pharm Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
EA200600372A1 (ru) *	2003-09-05	2006-08-25	Ньюроджин Корпорейшн	Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1)
US7208596B2 (en)	2003-11-25	2007-04-24	Bristol-Myers Squibb Pharma Company	Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2 (en)	2003-11-25	2006-12-26	Bristol-Myers Squibb Pharma Co.	Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
GB0328243D0 (en)	2003-12-05	2004-01-07	Astrazeneca Ab	Methods
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
KR20070009537A (ko)	2003-12-22	2007-01-18	에스비 팜코 푸에르토 리코 인크.	Ｃｒｆ 수용체 길항제 및 그와 관련된 방법
MY145634A (en)	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
US7557111B2 (en)	2004-01-06	2009-07-07	Taisho Pharmaceutical Co., Ltd.	Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
CA2552503C (en)	2004-01-06	2011-09-13	Taisho Pharmaceutical Co., Ltd.	Pyrrolopyrimidine and pyrrolotriazine derivatives
SG150511A1 (en)	2004-02-20	2009-03-30	Boehringer Ingelheim Int	Viral polymerase inhibitors
US7102002B2 (en)	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7102003B2 (en)	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en)	2004-08-12	2006-06-16	Bristol Myers Squibb Co	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
ATE430746T1 (de) *	2004-10-19	2009-05-15	Smithkline Beecham Cork Ltd	Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7151176B2 (en)	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
JP5089395B2 (ja)	2004-10-29	2012-12-05	バイオクライストファーマシューティカルズ，インコーポレイテッド	治療用フロピリミジンおよびチエノピリミジン
US7674822B2 (en)	2004-11-24	2010-03-09	Wyeth	PTP1b inhibitors
EP2537520A1 (en)	2005-03-29	2012-12-26	Biocryst Pharmaceuticals, Inc.	Hepatics C therapies
WO2006126718A1 (ja) *	2005-05-27	2006-11-30	Tanabe Seiyaku Co., Ltd.	ピラゾロピリミジン誘導体
TW200740820A (en)	2005-07-05	2007-11-01	Takeda Pharmaceuticals Co	Fused heterocyclic derivatives and use thereof
EP1915377A1 (en)	2005-07-22	2008-04-30	Sunesis Pharmaceuticals, Inc.	Pyrazolo pyrimidines useful as aurora kinase inhibitors
US20070078136A1 (en)	2005-09-22	2007-04-05	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
US7514435B2 (en)	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
BRPI0717070A2 (pt)	2006-09-20	2013-09-24	Lilly Co Eli	compostos de tiofeno pirazolopirimidina
MY146388A (en)	2006-09-20	2012-08-15	Lilly Co Eli	Thiazole pyrazolopyrimidines as crfi receptor antagonists
JP5513118B2 (ja)	2006-10-19	2014-06-04	シグナルファーマシューティカルズ，エルエルシー	ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
MX2010006748A (es)	2007-12-19	2010-08-18	Vertex Pharma	Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
WO2009126624A1 (en)	2008-04-11	2009-10-15	Bristol-Myers Squibb Company	Triazolo compounds useful as dgat1 inhibitors
WO2009126861A2 (en)	2008-04-11	2009-10-15	Bristol-Myers Squibb Company	Triazolopyridine compounds useful as dgat1 inhibitors
NZ588376A (en)	2008-04-15	2011-06-30	Eisai R&D Man Co Ltd	3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
GB0906579D0 (en)	2009-04-16	2009-05-20	Vernalis R&D Ltd	Pharmaceuticals, compositions and methods of making and using the same
TWI491610B (zh)	2008-10-09	2015-07-11	必治妥美雅史谷比公司	作為激酶抑制劑之咪唑并嗒腈
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
EP2536720A1 (en)	2010-02-18	2012-12-26	Centro Nacional de Investigaciones Oncológicas (CNIO)	Triazolo [4, 5 - b]pyridin derivatives
US8912184B1 (en)	2010-03-01	2014-12-16	Alzheimer's Institute Of America, Inc.	Therapeutic and diagnostic methods
US8450320B2 (en) *	2010-04-16	2013-05-28	Abbvie Inc.	Pyrrolopyrazinone inhibitors of kinases
CN102971326A (zh)	2010-04-28	2013-03-13	百时美施贵宝公司	咪唑并哒嗪化合物及其在癌症中的用途
TWI541243B (zh)	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
EP2619198A1 (en)	2010-09-22	2013-07-31	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2638041B1 (en)	2010-11-12	2015-07-22	Bristol-Myers Squibb Company	Substituted azaindazole compounds
WO2012080232A1 (en)	2010-12-17	2012-06-21	Bayer Pharma Aktiengesellschaft	2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2014503521A (ja)	2010-12-17	2014-02-13	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類
CN103443100B (zh)	2010-12-17	2016-03-23	拜耳知识产权有限责任公司	在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
ES2691745T3 (es)	2011-04-08	2018-11-28	Janssen Sciences Ireland Uc	Derivados de pirimidina para el tratamiento de infecciones víricas
US10953012B2 (en) *	2011-04-26	2021-03-23	Bioenergenix Llc	Heterocyclic compounds for the inhibition of pask
US8969586B2 (en)	2011-09-27	2015-03-03	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
HUE040541T2 (hu)	2011-11-09	2019-03-28	Janssen Sciences Ireland Uc	Purin-származékok vírusfertõzések kezelésére
US9512126B2 (en)	2012-03-14	2016-12-06	Bayer Intellectual Property Gmbh	Substituted imidazopyridazines
ES2607184T3 (es) *	2012-07-09	2017-03-29	Janssen Pharmaceutica, N.V.	Inhibidores de la enzima fosfodiesterasa 10
KR102207888B1 (ko)	2012-07-13	2021-01-26	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	바이러스 감염증의 치료를 위한 거대환식 푸린
WO2014020041A1 (en)	2012-08-02	2014-02-06	Bayer Pharma Aktiengesellschaft	Combinations for the treatment of cancer
EA202090662A3 (ru)	2012-10-10	2020-08-31	Янссен Сайенсиз Айрлэнд Юси	ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
WO2014066795A1 (en)	2012-10-25	2014-05-01	Bioenergenix	Heterocyclic compounds for the inhibition of pask
WO2014066743A1 (en)	2012-10-25	2014-05-01	Bioenergenix	Heterocyclic compounds for the inhibition of pask
SG11201503042QA (en)	2012-11-16	2015-06-29	Janssen Sciences Ireland Uc	Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EP2958900B1 (en)	2013-02-21	2019-04-10	Janssen Sciences Ireland Unlimited Company	2-aminopyrimidine derivatives for the treatment of viral infections
RU2015143517A (ru)	2013-03-13	2017-04-19	Дженентек, Инк.	Пиразолсодержащие соединения и их применения
PT2978429T (pt)	2013-03-29	2017-05-24	Janssen Sciences Ireland Uc	Deaza-purinonas macrocíclicas para o tratamento de infeções virais
EP3004074B1 (en)	2013-05-24	2017-10-25	Janssen Sciences Ireland UC	Pyridone derivatives for the treatment of viral infections and further diseases
LT3008062T (lt)	2013-06-11	2017-06-12	Bayer Pharma Aktiengesellschaft	Pakeistųjų triazolpiridinų provaistų dariniai
WO2014207082A1 (en) *	2013-06-27	2014-12-31	Janssen R&D Ireland	Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
WO2015014815A1 (en)	2013-07-30	2015-02-05	Janssen R&D Ireland	THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
EP2940022B1 (en) *	2014-04-30	2020-09-02	Masarykova Univerzita	Furopyridines as inhibitors of protein kinases
JP6895378B2 (ja)	2015-01-06	2021-06-30	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態の処置方法
AU2016284162A1 (en)	2015-06-22	2018-02-01	Arena Pharmaceuticals, Inc.	Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
RU2699568C2 (ru) *	2015-12-21	2019-09-06	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Лиганды транслокаторного белка TSPO, обладающие антидепрессивной и ноотропной активностью
CA3027471A1 (en)	2016-07-01	2018-01-04	Janssen Sciences Ireland Unlimited Company	Dihydropyranopyrimidines for the treatment of viral infections
EA038646B1 (ru)	2016-09-29	2021-09-28	Янссен Сайенсиз Айрлэнд Анлимитед Компани	Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
CN110996943A (zh)	2017-08-14	2020-04-10	云杉生物科学公司	促肾上腺皮质激素释放因子受体拮抗剂
TW201945003A (zh)	2018-03-01	2019-12-01	愛爾蘭商健生科學愛爾蘭無限公司	２，４－二胺基喹唑啉衍生物及其醫學用途
WO2019236757A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
CN108812546A (zh) *	2018-09-07	2018-11-16	四川省草原科学研究院	适于青藏高原地区牦牛运输减少应激的药物及使用方法
EP4175572A4 (en)	2020-08-12	2024-03-27	Spruce Biosciences, Inc.	METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARIAN SYNDROME
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
CA2194756A1 (en) *	1995-05-12	1996-11-14	Jun Yuan	Novel deazapurine derivatives; a new class of crf1 specific ligands

1997
- 1997-07-25 NZ NZ333302A patent/NZ333302A/xx unknown
- 1997-07-25 EP EP97930697A patent/EP0923582B1/en not_active Revoked
- 1997-07-25 SK SK233-99A patent/SK23399A3/sk unknown
- 1997-07-25 PL PL97332040A patent/PL332040A1/xx unknown
- 1997-07-25 EA EA199900165A patent/EA002769B1/ru not_active IP Right Cessation
- 1997-07-25 KR KR1019997001674A patent/KR20000035934A/ko not_active Application Discontinuation
- 1997-07-25 TR TR1999/00389T patent/TR199900389T2/xx unknown
- 1997-07-25 CZ CZ99681A patent/CZ68199A3/cs unknown
- 1997-07-25 BR BR9711970A patent/BR9711970A/pt not_active Application Discontinuation
- 1997-07-25 DE DE69736711T patent/DE69736711T2/de not_active Expired - Fee Related
- 1997-07-25 HU HU9903965A patent/HUP9903965A3/hu unknown
- 1997-07-25 AU AU34561/97A patent/AU735401B2/en not_active Ceased
- 1997-07-25 JP JP51142998A patent/JP3621706B2/ja not_active Expired - Fee Related
- 1997-07-25 ES ES97930697T patent/ES2273369T3/es not_active Expired - Lifetime
- 1997-07-25 WO PCT/IB1997/000922 patent/WO1998008847A1/en not_active Application Discontinuation
- 1997-07-25 CN CN97197027A patent/CN1227554A/zh active Pending
- 1997-07-25 CA CA002263566A patent/CA2263566C/en not_active Expired - Fee Related
- 1997-07-25 IL IL12756697A patent/IL127566A0/xx unknown
- 1997-07-25 AT AT97930697T patent/ATE340176T1/de not_active IP Right Cessation
- 1997-08-12 PA PA19978436201A patent/PA8436201A1/es unknown
- 1997-08-21 AP APAP/P/1997/001077A patent/AP762A/en active
- 1997-08-22 HR HR970454A patent/HRP970454B1/xx not_active IP Right Cessation
- 1997-08-25 TW TW086112194A patent/TW575573B/zh active
- 1997-08-25 GT GT199700095A patent/GT199700095A/es unknown
- 1997-08-25 PE PE1997000756A patent/PE108898A1/es not_active Application Discontinuation
- 1997-08-26 ID IDP972962A patent/ID18249A/id unknown
- 1997-08-26 AR ARP970103861A patent/AR015103A1/es not_active Application Discontinuation
- 1997-08-27 DZ DZ970150A patent/DZ2300A1/fr active
- 1997-08-27 ZA ZA977687A patent/ZA977687B/xx unknown
- 1997-08-27 MA MA24779A patent/MA26438A1/fr unknown
- 1997-08-27 TN TNTNSN97145A patent/TNSN97145A1/fr unknown
- 1997-08-28 CO CO97049895A patent/CO4600634A1/es unknown
1999
- 1999-01-29 IS IS4963A patent/IS4963A/is unknown
- 1999-02-17 OA OA9900035A patent/OA10977A/en unknown
- 1999-02-22 BG BG103189A patent/BG103189A/xx unknown
- 1999-02-26 NO NO19990927A patent/NO313636B1/no not_active IP Right Cessation
2004
- 2004-09-21 JP JP2004273978A patent/JP2005047930A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AP9701077A0 (en)	1997-10-31
BR9711970A (pt)	1999-08-24
EA002769B1 (ru)	2002-08-29
AU3456197A (en)	1998-03-19
CZ68199A3 (cs)	1999-11-17
CA2263566C (en)	2003-09-09
JP3621706B2 (ja)	2005-02-16
NO990927D0 (no)	1999-02-26
HUP9903965A3 (en)	2002-02-28
HUP9903965A2 (hu)	2000-03-28
EA199900165A1 (ru)	1999-08-26
TR199900389T2 (xx)	2000-06-21
ES2273369T3 (es)	2007-05-01
MA26438A1 (fr)	2004-12-20
WO1998008847A1 (en)	1998-03-05
IS4963A (is)	1999-01-29
AR015103A1 (es)	2001-04-18
DZ2300A1 (fr)	2002-12-25
JP2000502723A (ja)	2000-03-07
CO4600634A1 (es)	1998-05-08
PL332040A1 (en)	1999-08-16
GT199700095A (es)	1999-02-16
PA8436201A1 (es)	1999-12-27
BG103189A (en)	1999-09-30
SK23399A3 (en)	2000-08-14
DE69736711D1 (de)	2006-11-02
NZ333302A (en)	2000-08-25
IL127566A0 (en)	1999-10-28
HRP970454B1 (en)	2002-10-31
HRP970454A2 (en)	1998-08-31
AU735401B2 (en)	2001-07-05
OA10977A (en)	2001-11-02
AP762A (en)	1999-09-13
CN1227554A (zh)	1999-09-01
TW575573B (en)	2004-02-11
NO990927L (no)	1999-02-26
ATE340176T1 (de)	2006-10-15
EP0923582B1 (en)	2006-09-20
PE108898A1 (es)	1999-01-26
ID18249A (id)	1998-03-19
DE69736711T2 (de)	2007-09-20
EP0923582A1 (en)	1999-06-23
NO313636B1 (no)	2002-11-04
JP2005047930A (ja)	2005-02-24
TNSN97145A1 (fr)	2005-03-15
KR20000035934A (ko)	2000-06-26
CA2263566A1 (en)	1998-03-05

Publication	Publication Date	Title
HRP970454B1 (en)	2002-10-31	Substituted 6,5-hetero-bicyclic derivatives
HK1019597A1 (en)	2000-02-18	Substituted 6, 6-hetero-bicyclic derivatives
GB2319250B (en)	1999-01-27	Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
IL128188A0 (en)	1999-11-30	,7-bicyclic derivatives substituted pyrido-or pyrimido-containing 6,6-or 6
IL141908A (en)	2003-04-10	1,4-benzodiazepine derivatives
HK1018216A1 (en)	1999-12-17	New 19-nor-pregnene derivatives.
PL329121A1 (en)	1999-03-15	Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
HK1018457A1 (en)	1999-12-24	Alkylaminobenzothiazole and-benzoxazole derivatives.
IL126624A0 (en)	1999-08-17	3-descladinose-2, 3-anhydroerythromycin derivatives
HU9802807D0 (en)	1999-02-01	1,3,8-triazo-spiro[4,5]decan-4-on derivatives
HRP970260A2 (en)	1998-04-30	2,4-diaminopyrimidine derivatives
GB2311779B (en)	1999-07-14	2,3 benzodiazepine derivatives
ZA974953B (en)	1997-12-08	Substituted pyrazolylpyrazole derivatives.
CY2322B1 (en)	2003-11-14	Benzoaeguequinoline derivatives.
ZA971167B (en)	1997-08-25	Heterocyclyl-ergoline derivatives.
HU9700609D0 (en)	1997-05-28	1,25-dihydroxy-12,22,23-trisdehydro-cholecalciferol derivatives
IL132162A (en)	2000-08-13	2,3-epoxypropionamide derivatives
IL132162A0 (en)	2001-03-19	2, 3-Epoxypropionamide derivatives
SI0920429T1 (en)	2003-06-30	Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
ZA965384B (en)	1997-01-24	4-Amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds
ZA972692B (en)	1998-03-23	Pyrrolopyrrolone derivatives.
ZA977881B (en)	1998-03-09	N-benzylazolium derivatives.